Internal Medicine, Medical Oncology · Palm Springs, FL
NPI
1568412930
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4801 S Congress Ave Ste 400
Palm Springs, FL, 33461
Phone (561) 366-4100
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.5M
244,635 services
Medicare patients, 2024
796
Average age 77
Drug cost, 2024
$11.0M
2,550 prescriptions
Company payments, 2025
$13K
From 51 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shachar Peles was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 28,620 times for 19 patients. In total Shachar Peles billed 244,635 services in 155 codes, and Medicare paid $4.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 28,620 | 19 | $39.04 | $1.1M |
| J9271 Injection, pembrolizumab, 1 mg | Office | 24,000 | 20 | $44.71 | $1.1M |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 19,320 | 13 | $0.22 | $4,172 |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 16,320 | 19 | $0.28 | $4,525 |
| J0897 Injection, denosumab, 1 mg | Office | 9,060 | 32 | $20.53 | $186K |
| J0185 Injection, aprepitant, 1 mg | Office | 7,020 | 15 | $1.33 | $9,358 |
| J1756 Injection, iron sucrose, 1 mg | Office | 6,200 | 15 | $0.18 | $1,105 |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 5,850 | 12 | $2.24 | $13K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 5,060 | 15 | $35.86 | $181K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 4,890 | 39 | $6.55 | $32K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 4,700 | 38 | $15.78 | $74K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,234 | 45 | $0.09 | $292 |
| 85025 Blood Count | Office | 2,701 | 652 | $7.60 | $21K |
| 36415 Venipuncture Blood Collection | Office | 2,434 | 639 | $8.64 | $21K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,521 | 30 | $0.73 | $1,106 |
By year: 2022 $5.2M for 393,615 services; 2023 $4.9M for 325,830 services; 2024 $4.5M for 244,635 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,701 | 652 | $7.60 | $21K |
| 36415 Venipuncture Blood Collection | 2,434 | 639 | $8.64 | $21K |
| 85046 Blood Count | 72 | 59 | $5.39 | $388 |
| 81003 Clinical Chemistry | 37 | 13 | $2.20 | $81.4 |
Medicare prescription drug claims, 2024
In 2024, the drug Shachar Peles prescribed most often to Medicare patients was Revlimid (Lenalidomide), with 197 prescriptions and refills. In total Shachar Peles wrote 2,550 Medicare prescriptions that cost $11.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | 197 | 197 | 24 | $3.3M |
| Eliquis Apixaban | 150 | 183 | 33 | $105K |
| Hydroxyurea Generic | 137 | 224 | 26 | $2,929 |
| Acyclovir Generic | 112 | 210 | 24 | $1,782 |
| Xarelto Rivaroxaban | 106 | 201 | 26 | $106K |
| Levothyroxine Sodium Generic | 101 | 245 | 30 | $1,081 |
| Dexamethasone Generic | 89 | 112 | 29 | $1,191 |
| Jakafi Ruxolitinib Phosphate | 88 | 88 | Under 11 | $1.3M |
| Xtandi Enzalutamide | 82 | 90 | Under 11 | $1.1M |
| Prednisone Generic | 79 | 97 | 21 | $473 |
| Gabapentin Generic | 75 | 81 | 22 | $990 |
| Anastrozole Generic | 67 | 166 | 22 | $1,339 |
| Prochlorperazine Maleate Generic | 56 | 56 | 39 | $578 |
| Valacyclovir Valacyclovir Hcl | 54 | 74 | 13 | $1,691 |
| Potassium Chloride Generic | 45 | 59 | 19 | $469 |
Brand drugs: - claims; generic drugs: 1,517 claims; opioid claims: 97.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shachar Peles $13K ($12K in general payments such as food, travel and fees and $1,524 for research) from 51 companies. The largest payer was Karyopharm Therapeutics Inc. with $5,014.
| Company | Payments | Amount |
|---|---|---|
| Karyopharm Therapeutics Inc. KPTI | 3 | $5,014 |
| F. Hoffmann-La Roche AG ROG.SW | 2 | $1,524 |
| Janssen Biotech, Inc. JNJ | 33 | $1,374 |
| GlaxoSmithKline, LLC. GSK | 15 | $1,062 |
| Geron Corporation GERN | 3 | $825 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $273 |
| Pfizer Inc. PFE | 22 | $270 |
| Abbvie Inc. ABBV | 12 | $253 |
| Celgene Corporation BMY | 13 | $238 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $228 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.